PhuturdexDrug Pipeline Intelligence

Phuturdex › Diseases › Heart failure

Drugs in development · updated 30 October 2026

Heart failure: drugs in development

As of 30 October 2026 there are 113 active clinical trials (recruiting or ongoing, phases I–III) on 104 drugs for heart failure. 41 are experimental, that is not yet approved in the United States.

113Active trials
41Experimental drugs
12Experimental, in phase III

Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.

Sign in free →

Experimental drugs

Not yet approved by the US FDA for any indication.

DrugMost advanced phaseActive trialsReference trial
TNX-103III3NCT07436689
VicadrostatIII3NCT06424288
HiCM-188III2NCT07496372
BalcinrenoneIII1NCT06307652
ElecoglipronIII1NCT07761117
LevosimendanIII1NCT04020263
Maridebart cafraglutideIII1NCT07037459
NNC0487-0111III1NCT07567001
Omecamtiv MecarbilKinharto®III1NCT06736574
PhosphocreatineIII1NCT06503016
Thiamine MononitrateIII1NCT05873881
ZiltivekimabIII1NCT06200207
CDR132LII3NCT06979362
AB-1002II1NCT05598333
AC01II1NCT07584967
AtibuclimabIC14I–II1NCT06556810
BMS-986435II1NCT06122779
CD34II1NCT06154044
CK-4021586II1NCT06793371
CRD-4730II1NCT07750873
EDG-15400II1NCT07795814
JK07II1NCT06369298
L-CarnitineCarnitineI–II1NCT03994874
MethylprednisoneII1NCT07461961
PF-07328948II1NCT06991257
RelaxinI–II1NCT07359872
Rubidium-82II1NCT06965621
SRD-001I–II1NCT04703842
XylitolD-xylitolI–II1NCT03994874
BQ-123I1NCT02966665
HB1011I1NCT07861035
HJB647I1NCT07465653
HRS-5765I1NCT07551167
HRS-7156I1NCT07601087
L-NMMAI1NCT02966665
LY3971297I1NCT07547540
MitoQMitoquinone MesylateI1NCT02966665
NNC0537-1482I1NCT07218627
SHR-4658I1NCT07230145
TN-401I1NCT06228924

Sorted by most advanced phase and number of active trials. Showing 40 of 41 drugs.

Approved drugs in new trials

Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.

DrugMost advanced phaseActive trialsReference trial
EmpagliflozinJardianceIII11NCT06424288
DapagliflozinForxiga, Dapagliflozin PropanediolII–III10NCT07469722
FinerenoneBAY94-8862, KerendiaIII9NCT07192952
ValsartanPrexxartan®, Diovan®III5NCT05508035
FurosemideLasix Onyu®, Furoscix®II–III4NCT07469722
SotagliflozinInpefa®, Zynquista®III4NCT06217302
ColchicineColchicin, Lodoco®III3NCT05873881
SacubitrilIII3NCT05508035
VericiguatVerquvo®II–III3NCT05714085
AcetazolamideDiamox®II–III2NCT07469722
InclisiranLeqvio®III2NCT06597006
SemaglutideWegovy, RybelsusIII2NCT07090343
Sodium Zirconium CyclosilicateLokelma®III2NCT06578078
ApixabanEliquis, Abanta®III1NCT07471139
AspirinVazalore®, Durlaza®III1NCT06082063

Sorted by most advanced phase and number of active trials. Showing 15 of 63 drugs.

All 104 drugs, with the details

In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.

Open in Phuturdex →

Specific forms

Broader categories

Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D006333 “Heart Failure”.

ItalianoFrançaisDeutsch